Cancerforskningsfondet Af 1989

Ann Louring Roldan

Ettore Appella

Vincent Ellis

Michael Ploug

Charles Pyke

Eeva-Marjatta Salonen

Niels Behrendt

Antti Vaheri

Francesco Blasi

Hannele Tapiovaara

Peter Kristensen

Maria Teresa Masucci

Ross W Stephens

Maria Vittoria Cubellis

Wolf-Dieter Schleuning

Keld Dano Slashed

Keld Dan&oslash;

Ebbe Ro Slashednne

Ebbe R&oslash;nne

Leif R&oslash;ge Lund

Wd Schleuning

L&aacute;szlo Patthy

Laszlo Patthy

Leif Ro Lund

Lisbeth Birk Mo Slashedller

Jari P&ouml;ll&auml;nen

Jari Pollanen

Lisbeth Birk M&oslash;ller

Activation of plasminogen to plasmin is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator receptor are provided.

Urokinase-type plasminogen activator receptor

Activation of plasminogen to plasma is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator are provided.

Vectors and methods for recombinant production of uPA-binding fragments

Growing community of inventors

Vallensbæk, Denmark

Ann Louring Roldan